{"id":1644,"date":"2023-06-25T17:29:04","date_gmt":"2023-06-25T17:29:04","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/aprepitant\/"},"modified":"2023-06-25T19:53:37","modified_gmt":"2023-06-25T19:53:37","slug":"aprepitant","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/aprepitant\/","title":{"rendered":"Aprepitant"},"content":{"rendered":"

<\/p>\n

Aprepitant<\/h1>\n

CLINICAL USE<\/h3>\n
  • Prevention of acute and delayed nausea
    \nand vomiting associated with moderate and
    \nhighly emetogenic cancer chemotherapy<\/p>\n

    DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

    125 mg once daily on day 1 followed by 80 mg
    \nonce daily on days 2 and 3<\/p>\n

    PHARMACOKINETICS<\/h3>\n<\/li>\n
  • Molecular weight                           :
    \n534.4<\/li>\n
  • %Protein binding                           :
    \n>95<\/li>\n
  • %Excreted unchanged in urine     :
    \n0<\/li>\n
  • Volume of distribution (L\/kg)       :
    \n66 litres<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :
    \n9\u201313\/Unchanged<\/p>\n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           :
    \nDose as in normal renal function<\/p>\n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :
    \nNot dialysed. Dose as in normal renal function<\/li>\n
  • HD                     :
    \nNot dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   :
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function<\/li>\n
  • CAV\/VVHD      :
    \nNot dialysed. Dose as in normal renal function<\/p>\n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n<\/li>\n
  • Potentially hazardous interactions with other drugs<\/li>\n
  • Avoid concurrent administration withpimozide or St John\u2019s wort<\/li>\n
  • Oestrogens and progestogens: may causecontraceptive failure
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n

    Less than 0.2% of a dose is recovered in<\/p>\n

    dialysate after haemodialysis<\/li>\n","protected":false},"excerpt":{"rendered":"

    Aprepitant CLINICAL USE Prevention of acute and delayed nausea and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1644","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1644"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1644\/revisions"}],"predecessor-version":[{"id":2903,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1644\/revisions\/2903"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}